A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration (Journal of Crohn's and Colitis, 2018)

(untitled) - Rowley, A; Taylor, M; Duggal, A; Foster, M; Sirohi, S; Solanke, Y; Walshe, C; Fyfe, M; Webber, S; Travis, S